CCRM established DeepTech Bio Lab to explore digital tools and advanced technologies for cell and gene therapy industrialization.
2
Access to capital is the primary bottleneck in cell and gene therapy, requiring demonstration of durable commercial success to attract investors.
3
Progress in reprogramming induced pluripotent stem cells for safe and effective therapies is significant but underappreciated.
4
The belief that cell and gene therapy development is entirely different from past experiences is challenged by historical parallels in treatment approaches.
5
Future drug development will increasingly rely on data, AI, and quantum platforms, transforming the industry towards 'techbio' alongside 'biotech'.
